FDA WARNING_LETTER - Beepothecary LLC - October 06, 2020

On October 23, 2020, the FDA and FTC issued a Warning Letter to BEEpothecary regarding unapproved and misbranded products related to COVID-19. The agencies reviewed the company's websites (www.beepothecary.us, www.beepothecary.square.site) and social media (Facebook, Instagram, Twitter) on July 22, 2020, and October 6, 2020.

The FDA observed that products like "Elderberry, Honey & Propolis Syrup," "BEEbread," and "BEEHive Delight" were offered for sale with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. These products are deemed unapproved new drugs under section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and misbranded drugs under section 502 (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)).

The letter cites the public health emergency and national emergency declarations for COVID-19 as context for urgent FDA action. BEEpothecary is required to immediately cease selling these unapproved products. The company